Physician profile
Stefanie Altmann
NPI 1912494188
$6,130.65
in general payments reported to CMS, 2019-2025
30 companies · $957 in 2025
The $957 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $491 · 2021: $1,118 · 2022: $1,854 · 2023: $385 · 2024: $763 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.49 | 2020-2025 | Skyrizi |
| Lilly USA, LLC | $787.27 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $515.72 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $475.79 | 2021-2025 | |
| Kerecis Limited | $465.24 | 2022-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Janssen Biotech, INC. | $391.78 | 2020-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $346.07 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $323.85 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $306.45 | 2019-2025 | |
| Incyte Corporation | $300.38 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $183.83 | 2019-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $178.99 | 2021-2024 | |
| Galderma Laboratories, L.P. | $149.12 | 2022-2024 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $139.27 | 2020-2023 | Jublia, Arazlo, Duobrii |
| Genentech USA, INC. | $127.50 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $111.76 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.47 | 2024-2025 | Spevigo |
| Almirall LLC | $70.20 | 2020-2024 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $67.34 | 2020 | |
| Surgenex LLC | $45.83 | 2025 | Renograft, Surmatrix, Ardeograft |
| E.R. Squibb & Sons, L.L.C. | $42.65 | 2023-2025 | Sotyktu |
| Convatec INC. | $34.98 | 2024-2025 | |
| Amgen INC. | $34.96 | 2024-2025 | Otezla, Otezla |
| Smith+Nephew, INC. | $26.99 | 2025 | Collagenase Santyl |
| Blueprint Medicines Corporation | $24.48 | 2024 | Ayvakit |
| Verrica Pharmaceuticals INC. | $21.17 | 2025 | Ycanth |
| Biofrontera INC. | $19.28 | 2019 | |
| Dermira, INC. | $19.12 | 2020 | |
| Organon LLC | $16.61 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $15.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Altmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.